Department of Pathology, University of Michigan Medical School , Ann Arbor, Michigan, USA.
Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School , New Brunswick, New Jersey, USA.
J Clin Microbiol. 2023 Nov 21;61(11):e0007422. doi: 10.1128/jcm.00074-22. Epub 2023 Sep 28.
Antimicrobial susceptibility test and report guidelines are an important tool for antimicrobial stewardship programs. Since 1972, Tables 1 within the Clinical and Laboratory Standards Institute (CLSI) M100 document have provided a general framework upon which clinical microbiologists and antimicrobial stewardship teams can build algorithms for susceptibility testing and reporting that meet the specific needs of their institution. Many changes were made to Tables 1 in M100-Ed33 to modernize the content to reflect the landscape of current clinical practice, including the growing armamentarium of antimicrobial agents, the emergence of new mechanisms of antimicrobial resistance, the increasing prevalence of infections caused by multidrug-resistant organisms, and updated consensus recommendations for first-choice and alternative agents for treatment. With these items in mind, the CLSI Table 1 working group revised Tables 1 with the ultimate goal of supporting institutions in the creation of individualized test and report strategies that support local antimicrobial stewardship program initiatives. These strategies are built on the concepts of selective and cascade reporting. This minireview introduces the concept of CLSI M100-Ed33 Tables 1, describes the changes to Tables 1 introduced in 2023, and provides clinical vignettes that demonstrate how Tables 1 can be used in various scenarios to devise antimicrobial susceptibility test and report strategies.
抗菌药物敏感性试验和报告指南是抗菌药物管理计划的重要工具。自 1972 年以来,临床和实验室标准协会(CLSI)M100 文件中的表 1 为临床微生物学家和抗菌药物管理团队提供了一个通用框架,可以在此基础上构建满足其机构具体需求的药敏试验和报告算法。为了使内容现代化,以反映当前临床实践的情况,包括抗菌药物武器库的不断扩大、新的抗菌药物耐药机制的出现、多药耐药生物体引起的感染的流行率不断增加,以及更新的首选和替代治疗药物的共识建议,M100-Ed33 版对表 1 进行了许多修改。考虑到这些因素,CLSI 表 1 工作组对表 1 进行了修订,最终目标是支持各机构制定个体化的试验和报告策略,以支持当地的抗菌药物管理计划举措。这些策略建立在选择性和级联报告的概念之上。本文简要介绍了 CLSI M100-Ed33 表 1 的概念,描述了 2023 年引入的表 1 的变化,并提供了临床病例,展示了如何在各种情况下使用表 1 来设计抗菌药物敏感性试验和报告策略。